Eqis Capital Management Inc. Has $2.72 Million Position in Thermo Fisher Scientific Inc (TMO)
Eqis Capital Management Inc. increased its position in Thermo Fisher Scientific Inc (NYSE:TMO) by 5.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 14,391 shares of the medical research company’s stock after acquiring an additional 768 shares during the period. Eqis Capital Management Inc.’s holdings in Thermo Fisher Scientific were worth $2,723,000 at the end of the most recent reporting period.
Several other hedge funds have also recently added to or reduced their stakes in the stock. Proficio Capital Partners LLC increased its stake in Thermo Fisher Scientific by 71.5% during the 1st quarter. Proficio Capital Partners LLC now owns 607 shares of the medical research company’s stock valued at $105,000 after buying an additional 253 shares during the period. Cribstone Capital Management LLC increased its stake in Thermo Fisher Scientific by 8.7% during the 2nd quarter. Cribstone Capital Management LLC now owns 625 shares of the medical research company’s stock valued at $109,000 after buying an additional 50 shares during the period. Shine Investment Advisory Services Inc. acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $113,000. Chicago Partners Investment Group LLC acquired a new position in Thermo Fisher Scientific during the 2nd quarter valued at about $108,000. Finally, CWM LLC increased its stake in Thermo Fisher Scientific by 17.0% during the 2nd quarter. CWM LLC now owns 710 shares of the medical research company’s stock valued at $124,000 after buying an additional 103 shares during the period. 83.78% of the stock is currently owned by institutional investors and hedge funds.
Several equities analysts have commented on TMO shares. Leerink Swann raised their target price on shares of Thermo Fisher Scientific from $190.00 to $207.00 and gave the company an “outperform” rating in a research note on Monday, October 9th. Zacks Investment Research raised shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $212.00 price objective on the stock in a research note on Thursday, September 21st. Bank of America Corporation reaffirmed a “buy” rating and issued a $210.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Friday, July 21st. Cowen and Company reaffirmed an “outperform” rating and issued a $220.00 price objective (up previously from $200.00) on shares of Thermo Fisher Scientific in a research note on Sunday, September 10th. Finally, Deutsche Bank AG set a $226.00 target price on shares of Thermo Fisher Scientific and gave the stock a “buy” rating in a report on Thursday, October 26th. One investment analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company. The stock currently has an average rating of “Buy” and a consensus price target of $205.71.
In related news, insider Daniel P. Shine sold 2,026 shares of the business’s stock in a transaction on Wednesday, August 30th. The shares were sold at an average price of $180.97, for a total transaction of $366,645.22. Following the transaction, the insider now owns 20,682 shares of the company’s stock, valued at $3,742,821.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Peter E. Hornstra sold 3,894 shares of the business’s stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $185.18, for a total transaction of $721,090.92. Following the transaction, the vice president now directly owns 19,751 shares in the company, valued at approximately $3,657,490.18. The disclosure for this sale can be found here. In the last three months, insiders sold 22,738 shares of company stock worth $4,021,512. Insiders own 0.49% of the company’s stock.
Thermo Fisher Scientific Inc (TMO) opened at $186.18 on Monday. The firm has a market cap of $74,657.32, a P/E ratio of 20.46, a P/E/G ratio of 1.71 and a beta of 1.08. The company has a current ratio of 1.26, a quick ratio of 0.81 and a debt-to-equity ratio of 0.85. Thermo Fisher Scientific Inc has a 52-week low of $139.07 and a 52-week high of $201.20.
Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings data on Wednesday, October 25th. The medical research company reported $2.31 earnings per share for the quarter, beating the consensus estimate of $2.24 by $0.07. Thermo Fisher Scientific had a net margin of 11.73% and a return on equity of 15.94%. The firm had revenue of $5.12 billion for the quarter, compared to analyst estimates of $5.03 billion. During the same quarter last year, the firm earned $2.03 earnings per share. The company’s revenue for the quarter was up 13.9% on a year-over-year basis. equities analysts expect that Thermo Fisher Scientific Inc will post 9.36 EPS for the current year.
The company also recently declared a quarterly dividend, which will be paid on Monday, January 15th. Stockholders of record on Friday, December 15th will be given a $0.15 dividend. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.32%. The ex-dividend date of this dividend is Thursday, December 14th. Thermo Fisher Scientific’s dividend payout ratio is 10.19%.
WARNING: “Eqis Capital Management Inc. Has $2.72 Million Position in Thermo Fisher Scientific Inc (TMO)” was reported by Daily Political and is the property of of Daily Political. If you are accessing this piece on another website, it was illegally copied and republished in violation of U.S. and international trademark & copyright law. The legal version of this piece can be read at https://www.dailypolitical.com/2017/11/13/eqis-capital-management-inc-has-2-72-million-position-in-thermo-fisher-scientific-inc-tmo.html.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc develops, manufactures and sells a range of products. The Company provides analytical instruments, equipment, reagents and consumables, software and services for research, manufacturing, analysis, discovery and diagnostics. It operates through four segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific Inc and related companies with MarketBeat.com's FREE daily email newsletter.